[Skip to Content]
[Skip to Content Landing]
May 29, 1943


JAMA. 1943;122(5):298. doi:10.1001/jama.1943.72840220003007a

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


As this new drug has been presented to the medical profession, it is desirable that any untoward reactions from it be brought to the immediate attention of the physician.

Paredrine-sulfathiazole suspension is a preparation introduced by the Smith, Kline and French Pharmaceutical Company. The active components are a suspension of microcrystal sulfathiazole 5 per cent in an isotonic solution of 1 per cent paredrine hydrobromide (p-hydroxy-a-methylphenethylamine). The preservative used is sodium ethyl mercuri thiosalicylate 0.005 per cent; gelatin is present in 0.1 per cent. The product has been recommended by its makers as a vasoconstrictor of the nasal mucosa, with the additional value of the antibacteriostatic action of sulfathiazole. It may be introduced into the nasal cavity and sinuses by drops, atomizer or the displacement method of Proetz. The cases under study have been treated at the Otolaryngological Clinic of the St. Louis University Group of Hospitals.

Case 1.—  C.

First Page Preview View Large
First page PDF preview
First page PDF preview